Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials
Company Announcements

Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials

Brainstorm Cell Therapeutics ( (BCLI) ) has issued an announcement.

Brainstorm Cell Therapeutics, Inc. has released a presentation highlighting its autologous cell therapy platform, NurOwn®, for neurological disorders such as ALS and MS. The company is progressing towards a Phase 3b trial, with finalized clinical site agreements and manufacturing capabilities in place. NurOwn® has shown promise in prior trials, demonstrating improvements in patients and robust biomarker data supporting its mechanism of action. The presentation also outlines the company’s experienced team and strategic milestones, including first patient enrollment expected by December 2024.

See more insights into BCLI stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyBrainStorm enters MOU with Pluri to support NurOwn trial
Catie PowersBrainstorm Cell Therapeutics (BCLI) Q3 Earnings Cheat Sheet
TheFlyBrainStorm regains compliance with Nasdaq
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App